• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Omicron Delays FDA Inspections, as Well as Planning of Foreign Inspections

Omicron Delays FDA Inspections, as Well as Planning of Foreign Inspections

January 10, 2022

Due to the Omicron variant of COVID-19, the FDA will postpone foreign inspection assignments that were scheduled to begin in February 2022, as well as postponing work not deemed mission-critical.

That nonessential work includes domestic and foreign surveillance inspections, investigations and sample collections that can’t be performed remotely or safely due to travel or social distancing concerns, said FDA spokesperson Devin Koontz.

While the FDA did not specifically note whether inspections under its Bioresearch Monitoring program are impacted by these new delays, it’s safe to assume they affect all of the agency’s purviews.

Some, like Kalah Auchincloss, executive vice president of regulatory compliance for compliance consulting firm Greenleaf Health, believe the FDA’s actions may be overkill.

“On the one hand, we are obviously in the midst of a huge surge of COVID-19 and the transmission rates of the Omicron variant are far greater than Delta or other variants, but at the same time, we have fairly high rates of vaccination among FDA inspectorates, and it seems like the data coming out show that omicron is not severe,” said Auchincloss. “So, I’m surprised that we’re back to this state we were in in March of 2020.”

Still, it may be the safer way to go for employees, she said, adding that she doesn’t think the delay will last long. “They’re trying to recalibrate and will probably resume delayed work in February if Omicron starts to fade, which it’s already doing in some places,” Auchincloss said.

The agency, Koontz said, will continue conducting mission-critical foreign inspections and will reassess plans as needed based on its monitoring of foreign travel conditions.

“Throughout the pandemic, we continued conducting mission-critical inspections across all FDA-regulated commodities regardless of physical site location, foreign and domestic,” Koontz said. “While the majority of mission-critical inspections have been domestic, we have successfully conducted mission-critical inspections in nearly 30 countries.”

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing